3,800
Participants
Start Date
September 30, 2021
Primary Completion Date
January 31, 2027
Study Completion Date
January 31, 2027
Nirmatrelvir/ritonavir (e.g. PAXLOVID™)
Nirmatrelvir 300mg BD for 5/7 Ritonavir 100mg BD for 5/7
Nitazoxanide
Nitazoxanide 1.5g BD 7/7
Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™)
Molnupiravir 800mg BD for 5/7, Nirmatrelvir 300mg BD for 5/7, Ritonavir 100mg BD for 5/7
Hydroxychloroquine
Hydroxychloroquine 400mg D0 BD and 400MG OD for a further 6/7
No treatment
No treatment (except antipyretics- paracetamol)
Monoclonal antibodies
Monoclonal antibodies: 300mg tixagevimab/ 300 mg cilgavimab given once on D0
Fluoxetine
Fluoxetine 40mg OD for 7/7
Molnupiravir
Molnupiravir 800mg BD for 5/7
Sotrovimab
Sotrovimab 500mg given once on D0
Ensitrelvir
Ensitrelvir 375mg OD D0 and 125mg OD for a further 4/7
Monoclonal antibodies
Monoclonal antibodies: 600mg casirivimab/ 600mg imdevimab given once on D0
Favipiravir
Favipiravir 1800mg BD D0 and 800mg BD for a further 6/7
Ivermectin
Ivermectin 600micrograms/kg/day for 7/7.
Remdesivir
Remdesivir 200mg D0 and 100mg for a further 4/7.
Atilotrelvir/ritonavir
Atilotrelvir 150mg BD for 5/7 Ritonavir 100mg BD for 5/7
Metformin
Metformin 500mg TDS 5/7
Nirmatrelvir/ritonavir
Nirmatrelvir 300mg BD for 5/7 Ritonavir 50mg BD for 5/7
Nirmatrelvir/ritonavir
Nirmatrelvir 150mg BD for 5/7 Ritonavir 50mg BD for 5/7
Nirmatrelvir
Nirmatrelvir 300mg BD for 5/7
TERMINATED
Vajira hospital, Bangkok
RECRUITING
Faculty of Tropical Medicine, Mahidol University, Bangkok
TERMINATED
Bangplee Hospital, Mueang Samut Prakan
RECRUITING
Universidade Federal de Minas Gerais, Minas Gerais
RECRUITING
Sukraraj Tropical & Infectious Disease Hospital, Kathmandu
TERMINATED
The Aga Khan University Hospital, Karachi
RECRUITING
Laos-Oxford-Mahosot Wellcome Trust Research Unit, Vientiane
University of Oxford
OTHER